![logo](/logos/HALO.webp)
Halozyme Therapeutics, Inc.
NASDAQ:HALO
59.21 (USD) • At close September 6, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Halozyme Therapeutics, Inc. |
Symbool | HALO |
Munteenheid | USD |
Prijs | 59.21 |
Beurswaarde | 7,500,604,380 |
Dividendpercentage | 0% |
52-weken bereik | 32.83 - 65.53 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Helen I. Torley M.B. Ch. B., M.R.C.P. |
Website | https://www.halozyme.com |
An error occurred while fetching data.
Over Halozyme Therapeutics, Inc.
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)